<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03079310</url>
  </required_header>
  <id_info>
    <org_study_id>107451</org_study_id>
    <nct_id>NCT03079310</nct_id>
  </id_info>
  <brief_title>Spinal Cord Stimulation for Gait in Parkinson Disease</brief_title>
  <official_title>Thoracic Dorsal Spinal Cord Stimulation for the Treatment of Gait and Balance Impairments in Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western University, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western University, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Balance and gait impairment increases the risk of falls and contributes to a reduced quality
      of life and shorter survival in Parkinson disease (PD) and atypical Parkinsonism patients. In
      preliminary case studies, electrical epidural spinal cord stimulation (SCS) has been shown to
      significantly improve gait, postural instability, rigidity, and tremor. Controlled studies
      for optimizing which stimulation settings produce the best clinical response for mobility and
      gait, and achieving these results chronically are all significant unmet needs. Using
      quantitative laboratory and mobile technologies to test a range of stimulation settings, this
      research study aims to determine which SCS parameters or combination of parameters is best
      suited to effectively alleviate disabling symptoms experienced by each patient.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tailored SCS programming</measure>
    <time_frame>3 weeks</time_frame>
    <description>Participants following SCS implantation will undergo 3 programming visits. 9 SCS programs will be tested in a repeated fashion on separate days and at different times of the day (morning vs afternoon). The SCS setting(s) to produce the best motor (gait) response will be used by the participant in-home. SCS device will not be used during this time period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in spatiotemporal gait measures using objective gait analysis</measure>
    <time_frame>12 months</time_frame>
    <description>Spatiotemporal gait parameters known to be affected in parkinsonian syndromes will be analyzed over a 12 month period using gait analysis software. Best SCS setting tailored to each participant's gait symptoms will be assessed at 3-, 6- and 12-months time-points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in UPDRS-III scores</measure>
    <time_frame>12 months</time_frame>
    <description>UPDRS-III assessment will be assessed pre-surgery and post-surgery at 3-, 6- and 12-month time-points while participants are OFF/ON-dopaminergic medication and OFF/ON SCS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in NFOG-Q scores</measure>
    <time_frame>12 months</time_frame>
    <description>NFOG-Q scores will be assessed pre-surgery and post-surgery at 3-, 6- and 12-month time-points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PDQ-39 scores</measure>
    <time_frame>12 months</time_frame>
    <description>PDQ-39 scores will be assessed pre-surgery and post-surgery at 3-, 6- and 12-month time-points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ABC scores</measure>
    <time_frame>12 months</time_frame>
    <description>ABC scores will be assessed pre-surgery and post-surgery at 3-, 6- and 12-month time-points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in QoL scores</measure>
    <time_frame>12 months</time_frame>
    <description>QoL scores will be assessed pre-surgery and post-surgery at 3-, 6- and 12-month time-points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DaTscan imaging</measure>
    <time_frame>12-months</time_frame>
    <description>Asymmetry and specific binding ratios (SBRs) of the striatal regions of dopamine transporter from I-123 FP-CIT SPECT images will be quantitatively analyzed from pre-surgery and 12-months of SCS use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proprioception testing</measure>
    <time_frame>12-months</time_frame>
    <description>KINARM and lower leg KINARM type of robot collects reaction time, speed, force, accuracy and trajectory using a robotic object hitting game to assess cognitive and motor skills to be conducted pre-surgery, and post-SCS at 3-, 6- and 12-months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Atypical Parkinsonism</condition>
  <arm_group>
    <arm_group_label>Spinal cord stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Boston Scientific SCS system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spinal cord stimulation</intervention_name>
    <description>Range of pulse widths (200-500 microseconds) and frequencies (30-130 Hz) will be assessed for each patient</description>
    <arm_group_label>Spinal cord stimulation</arm_group_label>
    <other_name>Boston Scientific PrecisionÂ® System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consenting male and female participants, aged 18 years to 80 years

          -  Idiopathic PD with II-IV Hoehn-Yahn stage

          -  A history of frequent falls, gait and balance dysfunction and postural instability

          -  ON-freezing

          -  Ability to perform a gait/walking task (under close supervision),

          -  PD participants referred by Dr. Jog to the functional neurosurgeon for SCS
             implantation for treatment of their gait and balance dysfunction and/or for their
             freezing of gait.

          -  SCS eligibility has been confirmed by neurologist and neurosurgeon

          -  Patients who receive SCS for their gait and mobility must participate in this study in
             order to determine which SCS parameters provide the patient with the best outcome for
             their PD symptoms.

          -  able to give informed consent

          -  Able to attend all clinic visits and assessments

          -  No dementia or psychiatric abnormalities on neuropsychological testing

          -  No significant secondary causes (such as cerebrovascular disease, normal pressure
             hydrocephalus, peripheral neuropathy, severe degenerative lower limb or back disease).

               -  we had a few devices to include exploratory trial in atypical PD (MSA, PSP, and
                  CBD confirmed diagnosis from clinic).

        Exclusion Criteria:

          -  History of stroke

               -  History of ALS or Myasthenia Gravis

               -  Offending medications (Lithium, valproate, steroids, amiodarone, beta-adrenergic
                  agonists (e.g. salbutamol).

               -  Persons prescribed zonisamide

               -  Women reporting that they are pregnant

               -  Persons medically unstable with contraindications to SCS will be excluded

               -  Previous brain surgery or cardiac pacemaker

               -  Eligibility for deep brain stimulation surgery

               -  Moderately severe parkinsonism in the context of unstable pharmacological
                  treatment

               -  Dementia as assessed by DSM criteria or severe cognitive disturbances

               -  Severe psychiatric symptoms (in particular, hallucinations and depression)

               -  Bad general health

               -  Lack of compliance at follow-up

               -  Severe dyskinesias

               -  Significant cognitive impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mandar Jog, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LHSC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mandar Jog, MD</last_name>
    <phone>519-685-8500</phone>
    <phone_ext>76708</phone_ext>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivia Samotus, MSc</last_name>
    <phone>519-685-8500</phone>
    <phone_ext>32059</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandar Jog, MD</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>32758</phone_ext>
      <email>mandar.jog@lhsc.on.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Fuentes R, Petersson P, Nicolelis MA. Restoration of locomotive function in Parkinson's disease by spinal cord stimulation: mechanistic approach. Eur J Neurosci. 2010 Oct;32(7):1100-8. doi: 10.1111/j.1460-9568.2010.07417.x. Review.</citation>
    <PMID>21039949</PMID>
  </reference>
  <reference>
    <citation>Santana MB, Halje P, SimplÃ­cio H, Richter U, Freire MAM, Petersson P, Fuentes R, Nicolelis MAL. Spinal cord stimulation alleviates motor deficits in a primate model of Parkinson disease. Neuron. 2014 Nov 19;84(4):716-722. doi: 10.1016/j.neuron.2014.08.061. Epub 2014 Oct 30.</citation>
    <PMID>25447740</PMID>
  </reference>
  <reference>
    <citation>Jenkinson N, Nandi D, Muthusamy K, Ray NJ, Gregory R, Stein JF, Aziz TZ. Anatomy, physiology, and pathophysiology of the pedunculopontine nucleus. Mov Disord. 2009 Feb 15;24(3):319-28. doi: 10.1002/mds.22189.</citation>
    <PMID>19097193</PMID>
  </reference>
  <reference>
    <citation>Nagatsua T, Sawadab M. L-dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism Relat Disord. 2009 Jan;15 Suppl 1:S3-8. doi: 10.1016/S1353-8020(09)70004-5. Review.</citation>
    <PMID>19131039</PMID>
  </reference>
  <reference>
    <citation>Liu HG, Zhang K, Yang AC, Zhang JG. Deep brain stimulation of the subthalamic and pedunculopontine nucleus in a patient with Parkinson's disease. J Korean Neurosurg Soc. 2015 Apr;57(4):303-6. doi: 10.3340/jkns.2015.57.4.303. Epub 2015 Apr 24.</citation>
    <PMID>25932301</PMID>
  </reference>
  <reference>
    <citation>Stefani A, Lozano AM, Peppe A, Stanzione P, Galati S, Tropepi D, Pierantozzi M, Brusa L, Scarnati E, Mazzone P. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain. 2007 Jun;130(Pt 6):1596-607. Epub 2007 Jan 24.</citation>
    <PMID>17251240</PMID>
  </reference>
  <reference>
    <citation>Ferraye MU, DebÃ» B, Fraix V, Goetz L, Ardouin C, Yelnik J, Henry-Lagrange C, Seigneuret E, Piallat B, Krack P, Le Bas JF, Benabid AL, ChabardÃ¨s S, Pollak P. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease. Brain. 2010 Jan;133(Pt 1):205-14. doi: 10.1093/brain/awp229. Epub 2009 Sep 22.</citation>
    <PMID>19773356</PMID>
  </reference>
  <reference>
    <citation>Giladi N, Horak FB, Hausdorff JM. Classification of gait disturbances: distinguishing between continuous and episodic changes. Mov Disord. 2013 Sep 15;28(11):1469-73. doi: 10.1002/mds.25672. Review.</citation>
    <PMID>24132835</PMID>
  </reference>
  <reference>
    <citation>Fuentes R, Petersson P, Siesser WB, Caron MG, Nicolelis MA. Spinal cord stimulation restores locomotion in animal models of Parkinson's disease. Science. 2009 Mar 20;323(5921):1578-82. doi: 10.1126/science.1164901.</citation>
    <PMID>19299613</PMID>
  </reference>
  <reference>
    <citation>FÃ©nelon G, Goujon C, Gurruchaga JM, Cesaro P, Jarraya B, Palfi S, Lefaucheur JP. Spinal cord stimulation for chronic pain improved motor function in a patient with Parkinson's disease. Parkinsonism Relat Disord. 2012 Feb;18(2):213-4. doi: 10.1016/j.parkreldis.2011.07.015. Epub 2011 Aug 23.</citation>
    <PMID>21865071</PMID>
  </reference>
  <reference>
    <citation>Hassan S, Amer S, Alwaki A, Elborno A. A patient with Parkinson's disease benefits from spinal cord stimulation. J Clin Neurosci. 2013 Aug;20(8):1155-6. doi: 10.1016/j.jocn.2012.08.018. Epub 2013 Feb 26.</citation>
    <PMID>23453160</PMID>
  </reference>
  <reference>
    <citation>Agari T, Date I. Spinal cord stimulation for the treatment of abnormal posture and gait disorder in patients with Parkinson's disease. Neurol Med Chir (Tokyo). 2012;52(7):470-4.</citation>
    <PMID>22850494</PMID>
  </reference>
  <reference>
    <citation>Landi A, Trezza A, Pirillo D, Vimercati A, Antonini A, Sganzerla EP. Spinal cord stimulation for the treatment of sensory symptoms in advanced Parkinson's disease. Neuromodulation. 2013 May-Jun;16(3):276-9. doi: 10.1111/ner.12005. Epub 2012 Dec 10.</citation>
    <PMID>23227965</PMID>
  </reference>
  <reference>
    <citation>Yadav AP, Fuentes R, Zhang H, Vinholo T, Wang CH, Freire MA, Nicolelis MA. Chronic spinal cord electrical stimulation protects against 6-hydroxydopamine lesions. Sci Rep. 2014 Jan 23;4:3839. doi: 10.1038/srep03839.</citation>
    <PMID>24452435</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 8, 2017</study_first_submitted>
  <study_first_submitted_qc>March 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2017</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal cord stimulation</keyword>
  <keyword>gait analysis</keyword>
  <keyword>whole-body kinematics</keyword>
  <keyword>Parkinson's disease</keyword>
  <keyword>Neuromodulation</keyword>
  <keyword>Feature extraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

